Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A Gynecologic Oncology Group trial

Journal of Clinical Oncology

Volumn 29, Issue 1, 2011, Pages 69-75

  Matei, Daniela ^a   Sill, Michael W ^a   Lankes, Heather A ^a   DeGeest, Koen ^a   Bristow, Robert E ^a   Mutch, David ^a   Yamada, S Diane ^a   Cohn, David ^a   Calvert, Valerie ^a   Farley, John ^a   Petricoin, Emanuel F ^a   Birrer, Michael J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RASH; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 79951988792     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.7856     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Ozols R: Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma, in DeVita VT (ed): Cancer, Principles and Practice of Oncology Philadelphia, PA, Lippincott-Raven, 1997, pp 1502-1540
3. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001 (Pubitemid 32642183)
4. Bookman MA, Darcy KM, Clarke-Pearson D, et al: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283-290, 2003 (Pubitemid 46606157)
5. Yang-Feng TL, Li SB, Leung WY, et al: Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer 48:678-681, 1991
6. van't Veer LJ, Hermens R, van den Berg-Bakker LA, et al: Ras oncogene activation in human ovarian carcinoma. Oncogene 2:157-165, 1988
7. Mok SC, Bell DA, Knapp RC, et al: Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53:1489-1492, 1993 (Pubitemid 23113216)
8. Dokianakis DN, Varras MN, Papaefthimiou M, et al: Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids. Clin Exp Metastasis 17:293-297, 1999 (Pubitemid 29477574)
9. Chien CH, Chow SN: Point mutation of the ras oncogene in human ovarian cancer. DNA Cell Biol 12:623-627, 1993
10. Gemignani ML, Schlaerth AC, Bogomolniy F, et al: Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90:378-381, 2003 (Pubitemid 36952030)
11. Kurman RJ, Shih IeM: Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151-160, 2008 (Pubitemid 351450677)
12. Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol 18:S19-S32, 2005 (suppl 2)
13. Cuatrecasas M, Erill N, Musulen E, et al: K-ras mutations in nonmucinous ovarian epithelial tumors: A molecular analysis and clinicopathologic study of 144 patients. Cancer 82:1088-1095, 1998 (Pubitemid 28136522)
14. Cuatrecasas M, Villanueva A, Matias-Guiu X, et al: K-ras mutations in mucinous ovarian tumors: A clinicopathologic and molecular study of 95 cases. Cancer 79:1581-1586, 1997 (Pubitemid 27154791)
15. Singer G, Oldt R 3rd, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486, 2003 (Pubitemid 36432423)
16. McPhillips F, Mullen P, Monia BP, et al: Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 85:1753-1758, 2001 (Pubitemid 34081523)
17. Mullen P, McPhillips F, MacLeod K, et al: Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer. Clin Cancer Res 10:2100-2108, 2004 (Pubitemid 38375572)
18. Mullen P, McPhillips F, Monia BP, et al: Comparison of strategies targeting Raf-1 mRNA in ovarian cancer. Int J Cancer 118:1565-1571, 2006
19. Matei D, Emerson RE, Lai YC, et al: Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25:2060-2069, 2006
20. Schmandt RE, Broaddus R, Lu KH, et al: Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98:758-764, 2003 (Pubitemid 36959272)
21. Boocock CA, Charnock-Jones DS, Sharkey AM, et al: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87:506-516, 1995
22. Erber R, Thurnher A, Katsen AD, et al: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18:338-340, 2004
23. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858, 2006 (Pubitemid 46094197)
24. Kim S, Yazici YD, Calzada G, et al: Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6:1785-1792, 2007 (Pubitemid 46954055)
25. Murphy DA, Makonnen S, Lassoued W, et al: Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY45-9006). Am J Pathol 169:1875-1885, 2006
26. Paweletz CP, Charboneau L, Bichsel VE, et al: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981-1989, 2001
27. Petricoin EF 3rd, Bichsel VE, Calvert VS, et al: Mapping molecular networks using proteomics: A vision for patient-tailored combination therapy. J Clin Oncol 23:3614-3621, 2005
28. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
29. Kondo T, Nakazawa T, Murata S, et al: Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol 38:1810-1818, 2007
30. Schilder RJ, Sill MW, Chen X, et al: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study. Clin Cancer Res 11:5539-5548, 2005 (Pubitemid 41060831)
31. Chen TT, Ng TH: Optimal flexible designs in phase II clinical trials. Stat Med 17:2301-2312, 1998 (Pubitemid 28482675)
32. Cox D: Regression models and life tables. J Royal Stat Soc B 34:187-220, 1972
33. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983 (Pubitemid 14202071)
34. Buyse M, Piedbois P: On the relationship between response to treatment and survival time. Stat Med 15:2797-2812, 1996 (Pubitemid 27011058)
35. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006 (Pubitemid 46630627)
36. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300, 2006 (Pubitemid 46630787)
37. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719, 2008
38. Elser C, Siu LL, Winquist E, et al: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25:3766-3773, 2007 (Pubitemid 47372619)
39. Arnault JP, Wechsler J, Escudier B, et al: Keratocanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 27:e59-61, 2009
40. Dubauskas Z, Kunishige J, Prieto VG, et al: Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7:20-23, 2009
41. Hong DS, Reddy SB, Prieto VG, et al: Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 144:779-782, 2008 (Pubitemid 351846880)
42. Karreth FA, DeNicola GM, Winter SP, et al: C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell 36:477-486, 2009
43. Heidorn SJ, Milagre C, Whittaker S, et al: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221, 2010
44. McCormick F: How blocking Raf activates the MAPK pathway. Pigment Cell Melanoma Res 23:187-189, 2010
45. Burger RA: Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902-2908, 2007
46. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
47. Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76-82, 2008
48. Escudier B, Lassau N, Angevin E, et al: Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13:1801-1809, 2007
49. Tong FK, Chow S, Hedley D: Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70:107-114, 2006
50. Friday BB, Yu C, Dy GK, et al: BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 68:6145-6153, 2008
51. Dougherty MK, Müller J, Ritt DA, et al: Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17:215-224, 2005 (Pubitemid 40138617)
52. Welch S, Hirte H, Elit L, et al: CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib: A trial of the PMH Phase II Consortium. J Clin Oncol 25:278s, 2007 (suppl 18S; abstr 5519)
53. Welch S, Hirte H, Schilder RJ, et al: Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. J Clin Oncol 24:276s, 2006 (suppl 18S; abstr 5084)